Phase 2, Multicenter, 24-month, Randomized, Third-party Unblinded, Placebo-controlled, Parallel-group Amyloid Imaging Positron Emission Tomography (Pet) And Safety Trial Of Acc-001 And Qs-21 Adjuvant In Subjects With Early Alzheimer's Disease
Phase of Trial: Phase II
Latest Information Update: 29 Feb 2016
At a glance
- Drugs Vanutide cridificar (Primary) ; QS 21
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Pfizer
- 07 Jun 2017 Biomarkers information updated
- 24 Feb 2016 Primary endpoint has been amended as reported by ClinicalTrials.gov record.
- 13 Jun 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.